Well, a mixed IMS October 2008 monthly-bag, here: the overall market is rising albeit slightly (consider the Crestor "Juptier" effect, here!), and yet, Schering's Joint Venture is essentially flat, month over month -- (its share is now down to 10.3 percent, though) here are the raw numbers:
. . . .Total US Cholesterol Management Market
Oct 2008: 20,292
Sept 2008: 19,666
Total Merck/Schering-Plough Franchise
Oct 2008: 2,186
Sept 2008: 2,171
Oct. 2008: 1,207
Sept 2008: 1,202
Oct. 2008: 978
Sept. 2008: 969. . .
I think it unlikely that this is the actual Vytorin bottom -- we haven't begun to see the fall-off from state government "non-approved" lists, nor the switching now underway due to the clearly superior results that Crestor (a statin) boasts, via "Jupiter". Those effects ought to first really be apparent in the IMS numbers for the new year 2009.